MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

89bio, Inc. - Common Stock (NQ:ETNB)

14.84 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December ↗
 
Via Benzinga
Topics Economy
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 ↗
ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study ↗
The companies are both working on treatments for a liver disease known as MASH. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
89bio Provides Business Update and Outlook for 2025
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints 
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Participate in the UBS Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
News headline image
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Appoints Francis Sarena as Chief Operating Officer
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story